A procurement manager from a US distributor told me they evaluate three new microneedling suppliers every quarter. Their vetting process includes a facility audit, a sample evaluation, and a regulatory document review. Over the past 18 months, they passed on 11 out of 12 candidates because the regulatory package was incomplete. The most common gap? A missing or inadequate clinical evaluation report.
Setting Up a Clinical Evaluation Literature Search
One of the most overlooked aspects of regulatory compliance is the post-market surveillance (PMS) obligation. Under EU MDR, manufacturers must actively collect and analyze data on their devices throughout their lifetime on the market.
A PMS plan for microneedling cartridges should include:
Key Databases and Search Strategies
The PMS report must be updated at least annually for Class IIa devices. Failure to maintain PMS documentation is one of the most common non-conformities found during Notified Body surveillance audits.
For FDA-regulated devices, the equivalent is the medical device reporting (MDR) system. Manufacturers must report deaths within 30 days and serious injuries within 10 days of becoming aware of the event.
If your current supplier cannot produce a complete technical file, a sterilization validation package, or a biocompatibility report covering the full ISO 10993 series, you are carrying regulatory risk that should belong to the manufacturer. Transferring that risk back to your supply chain is a matter of proper supplier qualification.
About the author
We are a Chinese OEM/ODM manufacturer of microneedling cartridges with full regulatory documentation packages: ISO 13485, CE MDR technical files, FDA 510(k) submission support, and EO sterilization validation per ISO 11135. Every cartridge we ship is traceable to a batch record with complete quality documentation. Qualified buyers can request a regulatory package review through tbphp.
OEM buyers looking for a supplier with complete regulatory files can request a documentation review through tbphp.